Qilu Hospital
Jinan, Shandong, 250012, China
Location status: Recruiting
NCT Number: NCT04918524
Connective tissue disease (CTD) is a common group of autoimmune diseases, mainly including systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS) , and so on. APS is caused by autoimmune disorders that cause recurrent miscarriage, thrombosis, and thrombocytopenia, and often secondary to connective tissue diseases such as SLE. Undifferentiated connective tissue disease (UCTD) is currently considered to be an independent disease in the classification of CTD. And women of childbearing age who suffer UCTD is more common than that in other definite CTDs. Therefore, the impact of the disease flare and the influence of medicine on pregnancy and lactation are important for these patients who may suffer high-risk of abnormal pregnance.
Interested in participating?
Request Info20 year–45 year
Female
Observational
Jinan, Shandong, 250012, China
Location status: Recruiting
Objective: To study the risk factors of poor pregnancy outcomes in CTD patients, and evaluate impact of different therapies on the maternal and fetal health.
Methods: Our department and Shanghai Gothic Network Technology Co.Ltd. jointly established the chronic disease management of CTD patients during pregnancy and lactation by using Smart System of Disease Management (SSDM). With this platform, patients in pregnancy can consult with rheumatologists face to face and follow-up regularly.
Follow-up: Consultation and followup will be scheduled every 4 weeks from confirmed pregnancy until delivery.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1.Any known etiology of previous pregnancy loss:
4.Disease history as follows:
5.Women have been diagnosed with Systemic lupus erythematosus
5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
Other names: Pred
100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
Other names: HCQ
100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.
Other names: Asp
40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.
Other names: LMWH
Time frame: After 28 weeks of gestation
Percentage of all patients that lead to live birth after 28 weeks of gestation
Time frame: within 10 weeks of gestation
Spontaneous pregnancy loss within 10 weeks of gestation
Time frame: after 10 weeks of gestation
Spontaneous pregnancy loss after 10 weeks of gestation
Time frame: after 20 weeks of gestation
Spontaneous pregnancy loss after 20 weeks of gestation
Time frame: between 28 and 37 weeks of gestation
Live birth before 37 weeks of gestation
Time frame: after 28 weeks of gestation
newborns with low weight (<2500g)
Time frame: after 28 weeks of gestation
the number of participants complicated with premature rupture of membranes
Time frame: after 28 weeks of gestation
the number of participants complicated with placental abruption
Time frame: after 12 weeks of gestation
weight below the 10th percentile for the gestational age
Time frame: after 12 weeks of gestation
the number of participants whose B-ultrasound indicates low amniotic fluid during pregnancy
Time frame: after 12 weeks of gestation
the number of participants whose B-ultrasound indicates abnormal S / D values during pregnancy
Time frame: during pregnancy, an average of 10 months
the number of participants whose B-ultrasound indicates placental hematoma during pregnancy
Time frame: after 20 weeks of gestation
New-onset hypertension after 20 weeks of gestation, with or without proteinuria > 300mg/24h, with or without any organ damage with seizures
Time frame: through study completion, an average of 10 months
the number of participants who were diagnosed with gestational diabetes
Time frame: through study completion, an average of 10 months
the number of participants who were diagnosed with gestational hypertension
Time frame: at delivery
the number of participants whose placenta with infarction.
Contact information is provided by the study sponsor or research team.
Qiang Shu, Dr.
CONTACT
Shuting Li
CONTACT
Qilu Hospital of Shandong University
Other
The Clinical Features and Pregnancy Outcomes of Patients With Connective Tissue Disease :a Prospective Cohort Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06455384
Cancer, Cardiac Conditions
Toronto, Ontario, Canada
View Trial DetailsNCT06574581
Connective Tissue Diseases, Interstitial Lung Disease
Taichung, Taiwan
View Trial DetailsNCT07541638
Connective Tissue Diseases, Interstitial Lung Disease
Roma, Italy
View Trial DetailsNCT07283081
Connective Tissue Diseases, Disease
Bordeaux, France
View Trial Details